Journey Medical (NASDAQ:DERM) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Journey Medical (NASDAQ:DERM) announced its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03), FiscalAI reports. The firm had revenue of $18.97 million for the quarter, compared to analyst estimates of $20.32 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.

Journey Medical Price Performance

Shares of NASDAQ DERM traded down $0.05 during mid-day trading on Thursday, hitting $4.39. 180,500 shares of the stock were exchanged, compared to its average volume of 212,686. The company has a market cap of $123.89 million, a P/E ratio of -19.95 and a beta of 1.14. The stock’s fifty day simple moving average is $6.03 and its two-hundred day simple moving average is $6.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. Journey Medical has a twelve month low of $4.25 and a twelve month high of $9.56.

Analyst Ratings Changes

A number of brokerages recently commented on DERM. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. Wall Street Zen downgraded shares of Journey Medical from a “buy” rating to a “hold” rating in a research note on Saturday, October 17th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Journey Medical in a report on Monday, October 26th. Finally, B. Riley Financial reissued a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of Journey Medical in a report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Journey Medical presently has a consensus rating of “Hold” and an average target price of $14.00.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.